LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces a class action lawsuit has been filed against Emergent BioSolutions, Inc. ("Emergent" or the "Company") (NYSE: EBS) concerning possible violations of federal securities laws between January 11, 2016 and June 21, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm before the lead plaintiff deadline 60-days from today.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, Emergent issued materially false and misleading statements about its business and financial prospects, specifically relating to future lucrative contract renewals and demand from the U.S. government for its anthrax vaccine BioThrax. These statements caused the Company’s common stock to trade at artificially inflated prices, which certain defendants were able to sell.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.